Microchip Technology: Strong Cyclical Recovery Priced In; Maintain Equal-Weight

Core Conclusion

Microchip Technology (MCHP) delivered a materially above-seasonal March quarter and guided June quarter 11% QoQ, with bookings accelerating to a four-year high. The recovery is broadening beyond inventory restocking into genuine demand re-engagement, supported by secular AI connectivity wins (PCIe Gen6). However, the stock has surged ~50% in the past month and trades at a 28x forward P/E, above its historical average of 19x and at the high end of analog/MCU peers. With revenue still ~37% below peak and the valuation already discounting a strong rebound, risk/reward is balanced. We maintain Equal-weight with a $94 price target.

What the Market May Be Underpricing

The pace and durability of the recovery—particularly the transition from "inventory burn ending" to a replenishment cycle—is stronger than typical seasonality would imply. April was the highest bookings month in four years, book-to-bill well above 1, and distributor inventory is now below normal. Thousands of customers are re-engaging, suggesting the upturn is broad-based and may extend beyond a single restocking event. Separately, PCIe Gen6 retimer design wins have doubled from three to six in two quarters, displacing a competitor at a major OEM, indicating a structural data center connectivity growth driver that is not yet reflected in consensus revenue estimates.

But the market already appears to be pricing this in. The stock’s 50% one-month rally and 28x forward multiple imply expectations for a recovery that is already visible in near-term guidance. Unless the recovery overshoots significantly—which is not management's base case—the upside from here is limited.

Evidence Chain

1. Revenue and Guidance Beat with Broad-Based Acceleration

• March quarter revenue $1,311M, +10.6% QoQ vs. MSe $1,270M and consensus $1,264M.
• June quarter guide midpoint $1,456M, +11% QoQ, above MSe $1,394M and consensus $1,344M.
• Non-GAAP gross margin for June guided to 62.8% (MSe 62.6%, Street 61.2%) as inventory reserve charges roll off faster than expected.
• Microcontrollers +11.1% QoQ, Analog +14.4% QoQ, Other +5.2% QoQ—all above seasonal trends.

2. Demand Recovery Is Moving Beyond Inventory Correction

• Book-to-bill "well above one" across the board; April bookings strongest in four years.
• Distributor inventory now below normal; sell-through grew 11.4% QoQ; sell-in only modestly below sell-through.
• Management reports "thousands of customers re-engaging," signaling shift from correction to normal demand/replenishment.
• Backlog visibility improving into September quarter; customer expedites increasing as inventories lean.

3. Structural Growth in Data Center Connectivity

• PCIe Gen6 design wins have risen from three to six over two quarters; Gen6 retimer introduced with a win at a major OEM displacing a competitor.
• Secular traction also visible in storage/memory controllers, FPGA, Ethernet/networking, and aerospace & defense.
• This diversifies the recovery beyond legacy MCU/analog seasonality and makes it more durable.

4. Management Remains Disciplined on Pricing and Supply

• Lead times are extending in substrates, subcontract capacity, and foundry supply, but management calls the supply backdrop "manageable" rather than acute.
• MCHP is not raising prices like several peers; management frames this as a share-gain strategy and customer relationship builder. This is a more restrained pricing posture, which could limit margin upside versus competitors.

5. Stock Has Already Repriced

• MCHP has risen ~50% in the last month.
• Current P/E of 28x on CY27e EPS of $3.37 is at the top end of +1 standard deviation above its 19x historical average, in line with high-GM analog/MCU peers.
• Revenue is still ~37% below its cyclical peak, and consensus estimates already assume a strong recovery trajectory.

Key Risks

• Macroeconomic uncertainty: A prolonged downturn would delay the recovery and push revenue further from peak, making the current valuation unsustainable.
• Increased MCU competition: Incremental Chinese capacity and aggressive pricing from competitors could erode market share, especially if MCHP’s restrained pricing posture fails to protect margins.
• Debt and leverage concerns: Net leverage could increase if the recovery slows; the balance sheet carries significant debt that may limit financial flexibility.
• Customer trust and PSP overhang: Previous inventory build issues may slow customer re-engagement if demand proves more cyclical than structural.
• Pricing headwind: MCHP’s decision not to raise prices contrasts with peers; if the recovery extends, this could leave margin expansion on the table.

Valuation or Trading Implications

Our $94 price target is based on 28x CY27e non-GAAP EPS of $3.37, unchanged multiple. The 28x reflects the upper end of MCHP’s historical range, justified by the cyclical acceleration and in-line with high-GM analog/MCU peers. Downside to our base case: if macro headwinds delay the recovery and the stock reverts to a mid-cycle 25x multiple, a bear case of $69 is plausible. Upside: if the recovery overshoots and market share gains materialize, a bull case of $118 (31x CY27e EPS of $3.82) is possible. Current price of $101.58 sits slightly above our base case, implying limited absolute upside.

We would revisit our rating only if macro uncertainty fades and the MCU upcycle shows signs of strengthening beyond what is currently priced.

Appendix Data Summary

Key estimate changes: CY26 revenue up from $5,581M to $5,801M; CY26 EPS from $2.49 to $2.76. CY27 estimates largely unchanged.